Does Gender Affirming Hormone Therapy Increase the Risk of Kidney Disease?

被引:3
作者
Eckenrode, Han E. [1 ]
Carwie, J. Caroline [2 ]
Curtis, Lisa M. [1 ,3 ]
机构
[1] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL USA
[2] Univ Georgia, Div Biol Sci, Athens, GA USA
[3] Univ Alabama Birmingham, Div Nephrol, MCLM 531,1918 Univ Blvd, Birmingham, AL 35233 USA
基金
美国国家卫生研究院;
关键词
Sex differences; acute kidney injury; chronic kidney disease; transgender; SEX-DIFFERENCES; RENAL ISCHEMIA; TRANSGENDER; TESTOSTERONE; PROGRESSION; URINARY; NERVOSA; STATES; CARE;
D O I
10.1016/j.semnephrol.2022.10.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Kidney health and manifestation of disease in transgender men, women, and nonbinary individuals are not well understood. Transgender individuals commonly receive gender-affirming hormone therapy (GAHT) to align their outward appearance with their gender. Recent attention to the differences in fundamental kidney parameters has identified that transgender individuals may manifest levels of these biomarkers differently than their cisgender coun-terparts. Improving understanding of the differences in biomarkers and in the development of kidney disease is essential to providing appropriate kidney care to this vulnerable population. In this review, we introduce the current information related to GAHT and kidney health and highlight the significant gaps in our understanding of how GAHT may affect kidney physiology and pathophysiology. Semin Nephrol 42:151284 (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页数:7
相关论文
共 60 条
  • [1] [Anonymous], 2021, HIV INFECT RISK PREV, P2019
  • [2] [Anonymous], 2016, How Many Adults Identify as Transgender in the United States
  • [3] HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health
    Ascher, Simon B.
    Scherzer, Rebecca
    Estrella, Michelle M.
    Shigenaga, Judy
    Spaulding, Kimberly A.
    Glidden, David V.
    Mehrotra, Megha L.
    Defechereux, Patricia
    Gandhi, Monica
    Grant, Robert M.
    Shlipak, Michael G.
    Jotwani, Vasantha
    [J]. AIDS, 2020, 34 (05) : 699 - 706
  • [4] Improved renal ischemia tolerance in females influences kidney transplantation outcomes
    Aufhauser, David D., Jr.
    Wang, Zhonglin
    Murken, Douglas R.
    Bhatti, Tricia R.
    Wang, Yanfeng
    Ge, Guanghui
    Redfield, Robert R., III
    Abt, Peter L.
    Wang, Liqing
    Svoronos, Nikolaos
    Thomasson, Arwin
    Reese, Peter P.
    Hancock, Wayne W.
    Levine, Matthew H.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (05) : 1968 - 1977
  • [5] Blood Pressure Effects of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Adults
    Banks, Katherine
    Kyinn, Mabel
    Leemaqz, Shalem Y.
    Sarkodie, Eleanor
    Goldstein, Deborah
    Irwig, Michael S.
    [J]. HYPERTENSION, 2021, 77 (06) : 2066 - 2074
  • [6] LGBT healthcare disparities: What progress have we made?
    Bonvicini, Kathleen A.
    [J]. PATIENT EDUCATION AND COUNSELING, 2017, 100 (12) : 2357 - 2361
  • [7] Anorexia Nervosa and the Kidney
    Bouquegneau, Antoine
    Dubois, Bernard E.
    Krzesinski, Jean-Marie
    Delanaye, Pierre
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 60 (02) : 299 - 307
  • [8] Sex differences in cancer risk and outcomes after kidney transplantation
    Buxeda, Anna
    Redondo-Pachon, Dolores
    Perez-Saez, Maria Jose
    Crespo, Marta
    Pascual, Julio
    [J]. TRANSPLANTATION REVIEWS, 2021, 35 (03)
  • [9] Centers for Disease Control, CHRON KIDN DIS US
  • [10] Chronic Kidney Disease in the Transgender, Nonbinary, or Gender Diverse Person
    Collister, David
    Krakowsky, Yonah
    Potter, Emery
    Millar, Adam C.
    [J]. SEMINARS IN NEPHROLOGY, 2022, 42 (02) : 129 - 141